Peptide Inhibiting MMP2 for Skin Condition Improvement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by matrix metalloproteinases (MMPs) often involve toxic inhibitors with limited long-term safety, necessitating the development of less toxic and effective MMP inhibitors for conditions such as skin aging, inflammatory diseases, and cancer invasion.
Innovation Solution
A peptide with an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 is developed, exhibiting MMP2 inhibitory activity and collagen degradation inhibitory activity, which can be used in cosmetic and pharmaceutical compositions to improve skin conditions and treat MMP activity-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If toxic MMP inhibitors are used to treat diseases mediated by matrix metalloproteinases, then the therapeutic effect is improved, but the long-term safety is worsened
Solution Approach 1:
The patent changes the chemical parameters of MMP inhibitors by developing peptide-based compounds with specific amino acid sequences (SEQ ID NO: 1 and SEQ ID NO: 2) that have reduced toxicity compared to conventional synthetic inhibitors, while maintaining or improving their ability to inhibit MMP2 and collagen degradation
Solution Approach 2:
The patent employs peptides as temporary, biodegradable inhibitors that can be metabolized by the body, replacing long-lasting toxic synthetic inhibitors. These peptide inhibitors provide therapeutic effect when needed and are naturally eliminated, reducing accumulation and long-term toxicity
2Duration of action of moving object
If conventional MMP inhibitors are used, then the disease progression is slowed, but the side effects increase
Solution Approach 1:
The patent introduces peptide molecules as intermediary substances that mediate between the need to inhibit MMP activity and the requirement to minimize harm. These peptides specifically bind to MMP2 and collagen, providing targeted inhibition without the broad-spectrum toxicity of conventional inhibitors, thus controlling disease progression while reducing side effects
3Measurement precision
If peptide inhibitors with high specificity are developed, then the selectivity for MMP2 is improved, but the complexity of synthesis increases
Solution Approach 1:
The patent segments the inhibitor into individual amino acid units that can be sequentially assembled through standard peptide synthesis methods. The specific sequences (SEQ ID NO: 1: CTKIYDPVC and SEQ ID NO: 2: CPRHFNPVC) are built step-by-step using protected amino acids and coupling reagents, allowing high specificity for MMP2 while managing synthesis complexity through modular construction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively inhibits MMP2 activity, collagen degradation, and melanosome transfer, providing wrinkle relief, skin regeneration, and anti-inflammatory effects, making it suitable for improving skin conditions and treating various MMP-related diseases.
Implementation Method 1
A peptide with an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 is developed, exhibiting MMP2 inhibitory activity and collagen degradation inhibitory activity
Data Source
Figure 1a
Figure 1b
Figure 2a
AI summary
The present invention provides a peptide having activity to improve skin condition. The peptide of the present invention exhibits a very excellent effect in improving skin condition by inhibiting MMP2 activity. A composition containing the peptide of the present invention exhibits excellent biological activities, such as inhibiting collagen decomposition and melanosome migration, and thus can be used in wrinkle reduction, skin regeneration, skin elasticity improvement, anti-skin aging, wound regeneration, acne reduction, skin regeneration or skin whitening. The composition containing the peptide of the present invention can be used as a pharmaceutical composition for preventing or treating MMP activity-related diseases and inflammation diseases.